SPDR S&P Aerospace & Defense ETF (XAR)
- Previous Close
167.78 - Open
168.63 - Bid 169.06 x 800
- Ask 169.33 x 800
- Day's Range
167.28 - 169.50 - 52 Week Range
125.31 - 175.28 - Volume
24,472 - Avg. Volume
179,250 - Net Assets 2.71B
- NAV 167.57
- PE Ratio (TTM) 37.51
- Yield 0.57%
- YTD Daily Total Return 24.34%
- Beta (5Y Monthly) 1.06
- Expense Ratio (net) 0.35%
In seeking to track the performance of the S&P Aerospace & Defense Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the aerospace and defense segment of the S&P Total Market Index ("S&P TMI").
SPDR State Street Global Advisors
Fund Family
Industrials
Fund Category
2.71B
Net Assets
2011-09-28
Inception Date
Performance Overview: XAR
View MoreTrailing returns as of 11/20/2024. Category is Industrials.
People Also Watch
Holdings: XAR
View MoreTop 10 Holdings (46.06% of Total Assets)
Sector Weightings
Recent News: XAR
View More
Research Reports: XAR
View MoreRaising target price to $54.00
CALIFORNIA WATER SERVICE GRP has an Investment Rating of HOLD; a target price of $54.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetWhat does Argus have to say about MOS?
MOSAIC CO/THE has an Investment Rating of HOLD; a target price of $27.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetBiogen Earnings: Full-Year Guidance Raised; Early Leqembi Sales Encouraging but Uncertainty Remains
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
RatingPrice TargetASML: More Thoughts on the Selloff, Valuation, Intel, TSMC, High-NA EUV, China and More
ASML is the leader in photolithography systems used in the manufacturing of semiconductors. Photolithography is the process in which a light source is used to expose circuit patterns from a photo mask onto a semiconductor wafer. The latest technological advances in this segment allow chipmakers to continually increase the number of transistors on the same area of silicon, with lithography historically representing a high portion of the cost of making cutting-edge chips. ASML outsources the manufacturing of most of its parts, acting like an assembler. ASML’s main clients are TSMC, Samsung, and Intel.
RatingPrice Target